The Angeles Clinic featured at ASCO 2013
Paradigm-shifting therapy for all solid tumors
Immunotherapy, specifically immune checkpoint inhibitors targeting the PD-1/PD-l1 pathway, took center stage at ASCO. The Arie Crown theatre was the site of the Clinical Science Symposium in relation to these paradigm-shifting therapies where nearly 1,500 physicians, nurses, and collaborators were packed to hear about the therapies that would help not only melanoma patients but also those with lung, renal, ovarian and a host of other carcinomas.
The Angeles Clinic and Research Institute has been involved with PD-1/PD-L1 antibodies since their inception. We were the first to have the drug deemed by the FDA to be a “breakthrough” therapy, Lambrolizumab(MK-3475), available for our patients. This data was presented and simultaneously published in the New England Journal of Medicine (Hamid et al.). Dr. Hamid then presented ground breaking data with anti-PDL1 antibody MPDL328A in melanoma. We are currently accruing to a study of this agent in combination with the BRAF inhibitor vemurafenib.
Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center presenting data of the combination of the Anti-PD-1 antibody nivolumab in combination with Ipilimumab. This was also simultaneously presented in the NEJM. Much has been made of the data presented which showed high reponse rates with PD-1 directed therapy. We are proud to be the first site in the United States with the ability to offer this therapy (Ipilimumab and Nivolumab combination) to our patients through a major phase III collaborative effort. (Wolchok et al) The data is promising. So too is the fact that we have these first-in-class paradigm-shifting therapeutics available for our patients at The Angeles Clinic and Research Institute.
Phase 1 Clincal Program expands at The Angeles Clinic
Success developing targeted therapies in oncology depends on the ability to identify new targets and develop agents that hit those targets in an efficient manner. Major clinical advances in the care of common cancers have been made through participation of patients in Phase I clinical trials of agents that achieve this goal. Predictive oncology biomarkers - i.e., genes and genetic mutations, proteins and signalling pathways implicated in the proliferation and death of cancer cells - and their use to control tumor growth has been a major advancement allowing more efficacious therapy with decreased toxicity. Our collaboration with pharmaceutical partners has been instrumental in bringing this care to our patients. For more information; click here
The Angeles Clinic Breast Cancer Advisor
It is an exciting time full of promise in breast cancer care. Researchers and clinicians are continuing to move the field forward at a pace that is difficult to imagine, therefore a well educated public is also critical. It is for this reason that this newsletter has been created; dedicated to all who have experienced breast cancer and those who are simply interested in being informed. Click here
The Angeles Clinic featured at ASCO 2013
Paradigm-shifting therapy for all solid tumors
Immunotherapy, specifically immune checkpoint inhibitors targeting the PD-1/PD-l1 pathway, took center stage at ASCO. The Arie Crown theatre was the site of the Clinical Science Symposium in relation to these paradigm-shifting therapies where nearly 1,500 physicians, nurses, and collaborators were packed to hear about the therapies that would help not only melanoma patients but also those with lung, renal, ovarian and a host of other carcinomas.
The Angeles Clinic and Research Institute has been involved with PD-1/PD-L1 antibodies since their inception. We were the first to have the drug deemed by the FDA to be a “breakthrough” therapy, Lambrolizumab(MK-3475), available for our patients. This data was presented and simultaneously published in the New England Journal of Medicine (Hamid et al.). Dr. Hamid then presented ground breaking data with anti-PDL1 antibody MPDL328A in melanoma. We are currently accruing to a study of this agent in combination with the BRAF inhibitor vemurafenib.
Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center presenting data of the combination of the Anti-PD-1 antibody nivolumab in combination with Ipilimumab. This was also simultaneously presented in the NEJM. Much has been made of the data presented which showed high reponse rates with PD-1 directed therapy. We are proud to be the first site in the United States with the ability to offer this therapy (Ipilimumab and Nivolumab combination) to our patients through a major phase III collaborative effort. (Wolchok et al) The data is promising. So too is the fact that we have these first-in-class paradigm-shifting therapeutics available for our patients at The Angeles Clinic and Research Institute.
Phase 1 Clincal Program expands at The Angeles Clinic
Success developing targeted therapies in oncology depends on the ability to identify new targets and develop agents that hit those targets in an efficient manner. Major clinical advances in the care of common cancers have been made through participation of patients in Phase I clinical trials of agents that achieve this goal. Predictive oncology biomarkers - i.e., genes and genetic mutations, proteins and signalling pathways implicated in the proliferation and death of cancer cells - and their use to control tumor growth has been a major advancement allowing more efficacious therapy with decreased toxicity. Our collaboration with pharmaceutical partners has been instrumental in bringing this care to our patients. For more information; click here
The Angeles Clinic Breast Cancer Advisor
It is an exciting time full of promise in breast cancer care. Researchers and clinicians are continuing to move the field forward at a pace that is difficult to imagine, therefore a well educated public is also critical. It is for this reason that this newsletter has been created; dedicated to all who have experienced breast cancer and those who are simply interested in being informed. Click here